Abstract
Background: Human dihydroorotate dehydrogenase (hDHODH, EC 1.3.5.2), a flavindependent mitochondrial enzyme involved in de novo pyrimidine biosynthesis, is a validated therapeutic target for the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. However, human DHODH inhibitors have also been investigated as treatment for cancer, parasite infections (i.e. malaria) and viruses as well as in the agrochemicals industry.
Objective: An overview of current knowledge of hDHODH inhibitors and their potential uses in diseases where hDHODH is involved.
Method: This review focuses on recent advances in the development and application of hDHODH inhibitors, specifically covering the patent field, starting from a brief description of enzyme topography and of the strategies usually followed in designing its selective inhibitors.
Results: The most important and well-described novelty is the fact that the discovery, in the autumn of 2016, that hDHODH inhibitors are able to induce in vivo myeloid differentiation has led to the possibility of developing novel hDHODH based treatments for Acute Myelogenous Leukemia (AML).
Conclusion: The review will describe a variety of specific inhibitor classes and conclude on recent and future therapeutic perspectives for this target.
Keywords: Autoimmune diseases, brequinar, cancer, dihydroorotate dehydrogenase (DHODH), inhibitors, leflunomide, leukemia, melanoma.
Recent Patents on Anti-Cancer Drug Discovery
Title:Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy
Volume: 13 Issue: 1
Author(s): Marco L. Lolli, Stefano Sainas, Agnese C. Pippione, Marta Giorgis, Donatella Boschi and Franco Dosio*
Affiliation:
- Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin,Italy
Keywords: Autoimmune diseases, brequinar, cancer, dihydroorotate dehydrogenase (DHODH), inhibitors, leflunomide, leukemia, melanoma.
Abstract: Background: Human dihydroorotate dehydrogenase (hDHODH, EC 1.3.5.2), a flavindependent mitochondrial enzyme involved in de novo pyrimidine biosynthesis, is a validated therapeutic target for the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. However, human DHODH inhibitors have also been investigated as treatment for cancer, parasite infections (i.e. malaria) and viruses as well as in the agrochemicals industry.
Objective: An overview of current knowledge of hDHODH inhibitors and their potential uses in diseases where hDHODH is involved.
Method: This review focuses on recent advances in the development and application of hDHODH inhibitors, specifically covering the patent field, starting from a brief description of enzyme topography and of the strategies usually followed in designing its selective inhibitors.
Results: The most important and well-described novelty is the fact that the discovery, in the autumn of 2016, that hDHODH inhibitors are able to induce in vivo myeloid differentiation has led to the possibility of developing novel hDHODH based treatments for Acute Myelogenous Leukemia (AML).
Conclusion: The review will describe a variety of specific inhibitor classes and conclude on recent and future therapeutic perspectives for this target.
Export Options
About this article
Cite this article as:
Lolli L. Marco, Sainas Stefano , Pippione C. Agnese , Giorgis Marta , Boschi Donatella and Dosio Franco *, Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy, Recent Patents on Anti-Cancer Drug Discovery 2018; 13 (1) . https://dx.doi.org/10.2174/1574892812666171108124218
DOI https://dx.doi.org/10.2174/1574892812666171108124218 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy A Study on the Biological Activity of 2-thioxo-imidazolidin-4-ones
Letters in Drug Design & Discovery Role of Invariant Natural Killer T (iNKT) Cells in Systemic Lupus Erythematosus
Current Medicinal Chemistry Progress of Biological Agents on Psoriatic Arthritis
Current Pharmaceutical Biotechnology Complement and Microglia in the Neuropathogenesis of HIV Infection: Pro- and Anti-Inflammatory Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design Novel Controlled Release Solid Dispersion for the Delivery of Diclofenac Sodium
Current Drug Delivery Improving the Utility of Steroidal Anti-Inflammatories: Identification of Selective Glucocorticoid Receptor Modulators
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Gastrin-Releasing Peptide Receptor as a Molecular Target for Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Chlorophytum borivilianum: A White Gold for Biopharmaceuticals and Neutraceuticals
Current Pharmaceutical Biotechnology Diagnostic and Prognostic Potential of the Macrophage Specific Receptor CD163 in Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) A Comprehensive Review on the Biological and Pharmacological Activities of Rhodanine Based Compounds for Research and Development of Drugs
Mini-Reviews in Medicinal Chemistry Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Proteoglycans in Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Synthesis and Biological Evaluation of Some Hydrazone Derivatives as Anti-inflammatory Agents
Letters in Drug Design & Discovery Recent Developments in CE-MS Based Metabolomics
Current Analytical Chemistry Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Expression and Function of Angiomodulating Cytokines in Rheumatoid Arthritis and Experimental Arthritis: Important Therapeutic Targets
Current Immunology Reviews (Discontinued) The Role of Cartilage Oligomeric Matrix Protein (COMP) in Skeletal Disease
Current Drug Targets